One by-product of the recurring battles between Israel and its Arab neighbors is that Israel has developed a home-grown weapons industry that addresses its very specific needs.
Over the decades, this has included a number of cutting-edge technologies, from drones to night-vision equipment, which have been widely exported.
A more recent example is the Iron Dome, which was used throughout the latest conflict with Hamas in the Gaza Strip. The mobile missile defense system is capable of stopping short-range rockets from places like Gaza, the West Bank, and southern Lebanon.
Isaac Ben-Israel, a former director of the Defense Ministry's research and development program, says there was no technology in the world capable of doing that, so Israel had to develop its own system. The U.S. has subsequently provided funding to Israel to build additional anti-missile batteries.
"We did it because of our unique threat and our unique problem and ... this is what we do since 1948," he says, referring to year that Israel was founded.
As with previous battles, the Gaza conflict has damaged Israel's overall economy. The tally this time has been estimated at several billion dollars for Israel and is far greater for the Palestinians in Gaza.
But the fighting can also provide a boost to Israel's arms manufacturers, says Barbara Opall-Rome, the Israel bureau chief for the U.S. magazine Defense News.
Over the past five years, Israel has had military sales of around $7 billion annually, she says. "And it puts them the top five of the world's arms exporting nations," she adds.
In the latest operation against Hamas, new types of ammunition, bombs that can penetrate reinforced concrete buildings, and other equipment have been introduced on the battlefield. Opall-Rome says a new anti-guided missile defense system for tanks, called Trophy, performed well during ground operations in Gaza.
"It means a lot on the international arms market, and is certainly makes very good use of their added value that these systems are combat proven," she says.
Critics would object to that, saying the Israeli weapons are not so precise and caused heavy Palestinian civilian casualties. More than 2,000 Palestinians were killed, and various estimates put the civilian deaths at 50 percent to more than 80 percent of that total.
In addition, the Israel-Palestinian feud imposes a major limitation in Israeli weapons sales: the Arab boycott of anything made in Israel.
"The whole Arabian Gulf market, which is the number one market for purchasing foreign-made weaponry, that's cut off to them," says Opall-Rome.
She says China is also cut off to Israel arms manufacturers because of U.S. security concerns. And Israel faces similar U.S. pressure when it comes to possible sales to Russia.
India is one Israel's biggest customers, buying everything from ship and air defense systems to anti-tank missiles and drones. Israel also sells to other countries in Asia as well as Europe and Latin America.
She says Israel is a tiny domestic market so its arms industry needs to export nearly 80 percent of its goods in order to break even.
Some of the weapons are so unique, that no one else wants or needs them. Case in point is the Iron Dome. It's proven generally effective against Hamas rockets, which are made in Gaza workshops and are relatively unsophisticated. But no other country faces this persistent threat from short-range rockets.
The same holds true for the Arrow, an anti-ballistic missile system. Uzi Ruben, the former head of Israel's missile defence program, says the Arrow was designed to destroy long-range missiles coming from Iraq or Iran. It went into development in 1991 and took nine years to bring it to operation.
"It was never used, it was just deployed," he says.
One of the new technologies likely to emerge from this conflict will focus on detecting and destroying tunnels, like those used by Hamas to move fighters and weapons underground. Former defense researcher, Ben-Israel, says it's not likely to be a big seller on the international market.
"No one in the world is digging tunnels in order to penetrate let's say into the United States of America, and for terrorist attacks," he says.
Still, Ben-Israel says there will always be a global demand for sophisticated weapons — something Israel has become better at producing with each war.
Novelist and Miami Herald columnist Carl Hiaasen writes with passion and purpose about the state he loves. His latest book, Bad Monkey, is an offbeat murder mystery set in Key West.
Originally broadcast June 13, 2013.
The 68-year-old film director hitchhiked from Baltimore to San Francisco for his book Carsick. He says hitchhiking is "the worst beauty regimen ever" and admits he always kept his luggage with him.
Originally broadcast June 10.
U.S. officials believe more than 140 American have gone to fight in Syria and Iraq, but sometimes it's difficult to determine why, and if they plan to come home as terrorists.
All this week, NPR counterterrorism correspondent Dina Temple-Raston has been reporting about Americans who've gone abroad to fight alongside Islamic extremists. She joins Here & Now's Robin Young to talk about what she’s found.
Recent reports by Dina Temple-Raston:
- For Islamic State, Hitting The U.S. May Not Be A Top Priority (Aug. 29)
- Brooklyn Man Fights In Syria. Is He A Threat To The U.S.? (Aug. 28)
- U.S. Officials Try To Gauge Threat From American Fighters In Syria (Aug. 27)
Scientists are reporting strong evidence that the experimental Ebola drug ZMapp may be effective for treating victims of the devastating disease.
A study involving 18 rhesus macaque monkeys, published Friday in the journal Nature, found that the drug saved 100 percent of the animals even if they didn't receive the drug until five days after they had been infected. The study is the first to test ZMapp in a primate, which is considered a good model for how a drug might work in humans.
"I think it's significant and a very important step forward in the fight against the Ebola virus," Gary Kobinger of the Public Health Agency of Canada, who led the study, told reporters during a telephone briefing Friday.
Kobinger and others cautioned that it remains unclear how well the drug might work in humans, but the findings are encouraging. "I think it strongly supports that concept," said Kobinger, stressing that this was still "speculative."
Kobinger noted the animals that were saved in the study were days — perhaps even hours — away from dying when they received the drug, and had been exposed to higher levels of the virus.
"We could rescue animals who had advanced disease," he said. That suggests the drug might be able to save people up to 11 days after becoming infected, he said.
ZMapp is a combination of three types of proteins known as antibodies, which the immune system typically produces in response to an infection. In this case, the antibodies against Ebola were created in the laboratory and produced using genetically engineered tobacco plants.
The drug has already been used on a handful of victims of the current Ebola outbreak raging in West Africa, including two American missionaries who recovered. But doctors say it's unclear what role ZMapp may have played, if any. At least two other Ebola victims who received ZMapp, including a Spanish priest and a Liberian doctor, died.
But Mapp Biopharmaceutical Inc. of San Diego, which developed the drug, has said it has exhausted its inventory. It would take months to produce any significant new supplies. So it remains unclear how much of a role the drug could play in the current outbreak, even if it proves to be effective in humans.
Nonetheless, Kobinger and others say the results are significant in the fight against Ebola. Despite many years of trying, there currently are no drugs or vaccines that have been shown to be effective for preventing or treating Ebola.
"The development of ZMapp and its success in treating monkeys at an advanced stage of Ebola infection is a monumental achievement," wrote Thomas W. Geisbert of the University of Texas Medical Branch at Galveston in an article accompanying the study.